Medpace (NASDAQ:MEDP) Trading 1.3% Higher

Medpace Holdings, Inc. (NASDAQ:MEDPGet Free Report)’s share price rose 1.3% during mid-day trading on Wednesday . The stock traded as high as $405.92 and last traded at $403.77. Approximately 33,695 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 244,642 shares. The stock had previously closed at $398.52.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MEDP. StockNews.com raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Robert W. Baird boosted their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday, April 24th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and lifted their target price for the stock from $340.00 to $450.00 in a research report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and raised their price target for the stock from $282.00 to $452.00 in a research note on Thursday, February 15th. Finally, Deutsche Bank Aktiengesellschaft started coverage on Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price target for the company. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Get Our Latest Analysis on MEDP

Medpace Trading Up 1.8 %

The company has a 50-day moving average price of $397.09 and a 200 day moving average price of $339.13. The stock has a market capitalization of $12.57 billion, a P/E ratio of 41.37, a price-to-earnings-growth ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDPGet Free Report) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. During the same period in the prior year, the firm posted $2.27 earnings per share. The company’s quarterly revenue was up 17.7% on a year-over-year basis. As a group, research analysts expect that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

Insider Transactions at Medpace

In other Medpace news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total value of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at $1,995,940,186.62. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, major shareholder Medpace Investors, Llc sold 50,000 shares of Medpace stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO August J. Troendle sold 100,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. Insiders sold 209,224 shares of company stock valued at $84,618,441 in the last quarter. 20.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Medpace

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Medpace by 2.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,897 shares of the company’s stock valued at $2,114,000 after purchasing an additional 148 shares during the last quarter. Portside Wealth Group LLC boosted its stake in shares of Medpace by 14.8% in the fourth quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after buying an additional 183 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Medpace by 355.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,555 shares of the company’s stock worth $1,090,000 after acquiring an additional 2,774 shares during the period. Norden Group LLC raised its position in Medpace by 207.8% during the fourth quarter. Norden Group LLC now owns 5,014 shares of the company’s stock valued at $1,537,000 after acquiring an additional 3,385 shares in the last quarter. Finally, Summit Creek Advisors LLC boosted its position in Medpace by 110.7% in the 4th quarter. Summit Creek Advisors LLC now owns 48,557 shares of the company’s stock worth $14,884,000 after purchasing an additional 25,510 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

(Get Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.